Modelling of blood pressure outcomes in patients with and without established cardiovascular or renal disease following treatment with valsartan (the PREVIEW study)

Karen MacDonald, Heidi Brié, Stefaan Vancayzeele, Christopher Lee, John Bowles, Kathleen Piotrowski, Christine Hermans, Ivo Abraham

Research output: Contribution to journalArticle

Abstract

Background: Hypertensive patients with established cardiovascular or renal disease (ECVRD) have an added 10-year risk of cardiovascular events, classified by the European Society of Hypertension/European Society of Cardiology as 'very high'. Aims: To identify determinants of blood pressure (BP) outcomes in hypertensive patients with and without ECVRD treated in second-line with valsartan. Methods: This was a subgroup analysis comparing patients with and without ECVRD who participated in the PREVIEW study, a 90-day observational prospective effectiveness study of valsartan, conducted in Belgium. Two-level (patients 'nested' under physicians) hierarchical linear and logistic modelling of BP values and BP control (140/90 mmHg; 130/80 mmHg for diabetics) at 90 days was applied to data from 1107 patients with and 2087 patients without ECVRD treated with valsartan by 504 general practitioners. Results: Absolute reductions in BP were similar across subgroups, with minor variations in actual BP levels in general and by subgroup. Fewer patients with versus without ECVRD achieved targets for systolic BP, diastolic BP and combined systolic/diastolic BP control. Variability in BP values and control at 90 days attributable to a physician-level class effect ranged from 24.6% to 28.1% and 15.0% to 22.4%, respectively. Physician- and patient-related determinants of 90-day BP outcomes varied considerably between the two subgroups. Conclusion: Several determinants of BP outcomes were identified comparing patients with and without ECVRD, including amenable physician-level and patient-level factors and warning signs for continued risk of uncontrolled BP. ECVRD patients present with differential characteristics, conditions and determinants that mandate individualized attention to complement general evidence-based antihypertensive treatment.

Original languageEnglish (US)
Pages (from-to)124-134
Number of pages11
JournalArchives of Cardiovascular Diseases
Volume106
Issue number3
DOIs
StatePublished - Mar 2013

Fingerprint

Valsartan
Blood Pressure
Kidney
Therapeutics
Physicians

Keywords

  • Cardiovascular disease
  • Effectiveness
  • Hypertension
  • Renal disease
  • Valsartan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Modelling of blood pressure outcomes in patients with and without established cardiovascular or renal disease following treatment with valsartan (the PREVIEW study). / MacDonald, Karen; Brié, Heidi; Vancayzeele, Stefaan; Lee, Christopher; Bowles, John; Piotrowski, Kathleen; Hermans, Christine; Abraham, Ivo.

In: Archives of Cardiovascular Diseases, Vol. 106, No. 3, 03.2013, p. 124-134.

Research output: Contribution to journalArticle

MacDonald, Karen ; Brié, Heidi ; Vancayzeele, Stefaan ; Lee, Christopher ; Bowles, John ; Piotrowski, Kathleen ; Hermans, Christine ; Abraham, Ivo. / Modelling of blood pressure outcomes in patients with and without established cardiovascular or renal disease following treatment with valsartan (the PREVIEW study). In: Archives of Cardiovascular Diseases. 2013 ; Vol. 106, No. 3. pp. 124-134.
@article{522dd174c5aa4628bd64b9527f3bb996,
title = "Modelling of blood pressure outcomes in patients with and without established cardiovascular or renal disease following treatment with valsartan (the PREVIEW study)",
abstract = "Background: Hypertensive patients with established cardiovascular or renal disease (ECVRD) have an added 10-year risk of cardiovascular events, classified by the European Society of Hypertension/European Society of Cardiology as 'very high'. Aims: To identify determinants of blood pressure (BP) outcomes in hypertensive patients with and without ECVRD treated in second-line with valsartan. Methods: This was a subgroup analysis comparing patients with and without ECVRD who participated in the PREVIEW study, a 90-day observational prospective effectiveness study of valsartan, conducted in Belgium. Two-level (patients 'nested' under physicians) hierarchical linear and logistic modelling of BP values and BP control (140/90 mmHg; 130/80 mmHg for diabetics) at 90 days was applied to data from 1107 patients with and 2087 patients without ECVRD treated with valsartan by 504 general practitioners. Results: Absolute reductions in BP were similar across subgroups, with minor variations in actual BP levels in general and by subgroup. Fewer patients with versus without ECVRD achieved targets for systolic BP, diastolic BP and combined systolic/diastolic BP control. Variability in BP values and control at 90 days attributable to a physician-level class effect ranged from 24.6{\%} to 28.1{\%} and 15.0{\%} to 22.4{\%}, respectively. Physician- and patient-related determinants of 90-day BP outcomes varied considerably between the two subgroups. Conclusion: Several determinants of BP outcomes were identified comparing patients with and without ECVRD, including amenable physician-level and patient-level factors and warning signs for continued risk of uncontrolled BP. ECVRD patients present with differential characteristics, conditions and determinants that mandate individualized attention to complement general evidence-based antihypertensive treatment.",
keywords = "Cardiovascular disease, Effectiveness, Hypertension, Renal disease, Valsartan",
author = "Karen MacDonald and Heidi Bri{\'e} and Stefaan Vancayzeele and Christopher Lee and John Bowles and Kathleen Piotrowski and Christine Hermans and Ivo Abraham",
year = "2013",
month = "3",
doi = "10.1016/j.acvd.2012.11.006",
language = "English (US)",
volume = "106",
pages = "124--134",
journal = "Archives of Cardiovascular Diseases",
issn = "1875-2136",
publisher = "Elsevier Masson",
number = "3",

}

TY - JOUR

T1 - Modelling of blood pressure outcomes in patients with and without established cardiovascular or renal disease following treatment with valsartan (the PREVIEW study)

AU - MacDonald, Karen

AU - Brié, Heidi

AU - Vancayzeele, Stefaan

AU - Lee, Christopher

AU - Bowles, John

AU - Piotrowski, Kathleen

AU - Hermans, Christine

AU - Abraham, Ivo

PY - 2013/3

Y1 - 2013/3

N2 - Background: Hypertensive patients with established cardiovascular or renal disease (ECVRD) have an added 10-year risk of cardiovascular events, classified by the European Society of Hypertension/European Society of Cardiology as 'very high'. Aims: To identify determinants of blood pressure (BP) outcomes in hypertensive patients with and without ECVRD treated in second-line with valsartan. Methods: This was a subgroup analysis comparing patients with and without ECVRD who participated in the PREVIEW study, a 90-day observational prospective effectiveness study of valsartan, conducted in Belgium. Two-level (patients 'nested' under physicians) hierarchical linear and logistic modelling of BP values and BP control (140/90 mmHg; 130/80 mmHg for diabetics) at 90 days was applied to data from 1107 patients with and 2087 patients without ECVRD treated with valsartan by 504 general practitioners. Results: Absolute reductions in BP were similar across subgroups, with minor variations in actual BP levels in general and by subgroup. Fewer patients with versus without ECVRD achieved targets for systolic BP, diastolic BP and combined systolic/diastolic BP control. Variability in BP values and control at 90 days attributable to a physician-level class effect ranged from 24.6% to 28.1% and 15.0% to 22.4%, respectively. Physician- and patient-related determinants of 90-day BP outcomes varied considerably between the two subgroups. Conclusion: Several determinants of BP outcomes were identified comparing patients with and without ECVRD, including amenable physician-level and patient-level factors and warning signs for continued risk of uncontrolled BP. ECVRD patients present with differential characteristics, conditions and determinants that mandate individualized attention to complement general evidence-based antihypertensive treatment.

AB - Background: Hypertensive patients with established cardiovascular or renal disease (ECVRD) have an added 10-year risk of cardiovascular events, classified by the European Society of Hypertension/European Society of Cardiology as 'very high'. Aims: To identify determinants of blood pressure (BP) outcomes in hypertensive patients with and without ECVRD treated in second-line with valsartan. Methods: This was a subgroup analysis comparing patients with and without ECVRD who participated in the PREVIEW study, a 90-day observational prospective effectiveness study of valsartan, conducted in Belgium. Two-level (patients 'nested' under physicians) hierarchical linear and logistic modelling of BP values and BP control (140/90 mmHg; 130/80 mmHg for diabetics) at 90 days was applied to data from 1107 patients with and 2087 patients without ECVRD treated with valsartan by 504 general practitioners. Results: Absolute reductions in BP were similar across subgroups, with minor variations in actual BP levels in general and by subgroup. Fewer patients with versus without ECVRD achieved targets for systolic BP, diastolic BP and combined systolic/diastolic BP control. Variability in BP values and control at 90 days attributable to a physician-level class effect ranged from 24.6% to 28.1% and 15.0% to 22.4%, respectively. Physician- and patient-related determinants of 90-day BP outcomes varied considerably between the two subgroups. Conclusion: Several determinants of BP outcomes were identified comparing patients with and without ECVRD, including amenable physician-level and patient-level factors and warning signs for continued risk of uncontrolled BP. ECVRD patients present with differential characteristics, conditions and determinants that mandate individualized attention to complement general evidence-based antihypertensive treatment.

KW - Cardiovascular disease

KW - Effectiveness

KW - Hypertension

KW - Renal disease

KW - Valsartan

UR - http://www.scopus.com/inward/record.url?scp=84876287177&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876287177&partnerID=8YFLogxK

U2 - 10.1016/j.acvd.2012.11.006

DO - 10.1016/j.acvd.2012.11.006

M3 - Article

C2 - 23582674

AN - SCOPUS:84876287177

VL - 106

SP - 124

EP - 134

JO - Archives of Cardiovascular Diseases

JF - Archives of Cardiovascular Diseases

SN - 1875-2136

IS - 3

ER -